ApoPharma - DRIVING INNOVATION

   >  Treat  >  Alkeran®

Alkeran®

(Melphalan) Tablets 2 mg
(Melphalan) for Injection 50 mg

Alkeran® tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Alkeran for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Click here to view the Product Insert for the tablet form of Alkeran.

Click here to view the Product Insert for the injection form of Alkeran.

   INDICATIONS AND IMPORTANT SAFETY INFORMATION

ALKERAN (melphalan) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Melphalan is leukemogenic in humans.

Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.

*All other brand or product names located in this site are trademarks of their respective holders. © ApoPharma Inc. 2018. All rights reserved. | Privacy Policy
500x500